Compare DORM & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DORM | DNLI |
|---|---|---|
| Founded | 1978 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 1996 | 2017 |
| Metric | DORM | DNLI |
|---|---|---|
| Price | $137.84 | $22.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $160.25 | $34.33 |
| AVG Volume (30 Days) | 289.8K | ★ 2.0M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.14 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $2,130,319,000.00 | N/A |
| Revenue This Year | $9.70 | N/A |
| Revenue Next Year | $4.92 | $408.85 |
| P/E Ratio | $98.72 | ★ N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $98.45 | $12.58 |
| 52 Week High | $166.88 | $27.30 |
| Indicator | DORM | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 45.25 |
| Support Level | $134.63 | $18.27 |
| Resistance Level | $138.71 | $23.27 |
| Average True Range (ATR) | 4.26 | 1.38 |
| MACD | -0.16 | -0.55 |
| Stochastic Oscillator | 46.71 | 17.96 |
Dorman Products Inc is a supplier of original equipment parts for automobiles. It offers automotive and heavy-duty replacement parts, automotive hardware, brake parts, and fasteners for the automotive and heavy-duty aftermarket. The products are sold under the Dorman brand and its sub-brands OE Solutions, Help!, Conduct-Tite, Super ATV, etc., through aftermarket retailers, warehouse distributors, specialty markets, and salvage yards. The company operates through three business segments, which include Light Duty, Heavy Duty, and Specialty Vehicle. A majority of its revenue is generated from the Light Duty segment, which designs and markets replacement parts and fasteners mainly for passenger cars and light trucks. Geographically, it derives key revenue from the United States.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.